{"id":742277,"date":"2013-12-10T07:00:00","date_gmt":"2013-12-10T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/"},"modified":"2023-03-22T00:04:31","modified_gmt":"2023-03-22T04:04:31","slug":"merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/","title":{"rendered":"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931"},"content":{"rendered":"<p class=\"bwalignc\">       Data Monitoring Committee recommends continuation of Phase II\/III        EPOCH study in mild to moderate disease patients     <\/p>\n<p class=\"bwalignc\">       Merck also plans to initiate dosing in Phase III study of prodromal        disease patients     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today provided an update on the development program for MK-8931, a novel<br \/>\n      investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme<br \/>\n      (BACE) inhibitor. The Data Monitoring Committee (DMC) for the Phase<br \/>\n      II\/III \u201cEPOCH\u201d study in patients with mild to moderate Alzheimer&#8217;s<br \/>\n      disease recently completed its planned interim safety analysis and<br \/>\n      recommended that the trial continue to recruit patients, with no changes<br \/>\n      to the protocol.\n    <\/p>\n<p>\n      The DMC recommendation was made following a planned analysis of interim<br \/>\n      safety data that included a safety cohort of 200 patients treated with<br \/>\n      MK-8931 for at least 3 months. Based upon the DMC\u2019s recommendations,<br \/>\n      Merck will continue enrollment of the EPOCH study. In addition, Merck<br \/>\n      will initiate dosing in a new Phase III study (APECS study) evaluating<br \/>\n      MK-8931 in patients with amnestic mild cognitive impairment due to<br \/>\n      Alzheimer&#8217;s disease, also known as prodromal Alzheimer\u2019s disease.\n    <\/p>\n<p>\n      \u201cWe are pleased to receive the DMC\u2019s recommendation and look forward to<br \/>\n      continuing the clinical development program for MK-8931,\u201d said Dr. David<br \/>\n      Michelson, vice president, Neuroscience, Merck Research Laboratories.<br \/>\n      \u201cStudies to evaluate potential new treatment options are critical as the<br \/>\n      global health and financial burden of Alzheimer\u2019s disease grows.\u201d\n    <\/p>\n<p>\n      <b>About the EPOCH Study<\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01739348%3Fterm%3Dmk-8931%26rank%3D2&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=EPOCH&amp;index=1&amp;md5=d09d792a6294e5ec56242fe8ee671541\" rel=\"nofollow\">EPOCH<\/a><br \/>\n      is a randomized, placebo-controlled, parallel-group, double-blind Phase<br \/>\n      II\/III clinical trial to evaluate the efficacy and safety of two oral<br \/>\n      doses of MK-8931 (12 and 40 mg) administered daily versus placebo in<br \/>\n      patients with mild to moderate Alzheimer\u2019s disease. The Phase II portion<br \/>\n      of the trial also included a 60 mg dose to evaluate safety. The trial is<br \/>\n      anticipated to enroll up to 1,960 patients. The primary efficacy<br \/>\n      outcomes of the study are the change from baseline in Alzheimer&#8217;s<br \/>\n      Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and the<br \/>\n      change from baseline in the Alzheimer&#8217;s Disease Cooperative Study \u2013<br \/>\n      Activities of Daily Living (ADCS-ADL) score following 78 weeks of<br \/>\n      treatment.\n    <\/p>\n<p>\n      <b>About the APECS Study<\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01953601%3Fterm%3Dmk-8931%26rank%3D3&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=APECS&amp;index=2&amp;md5=77404c998e8158807126c3b88954dd48\" rel=\"nofollow\">APECS<\/a><br \/>\n      is a randomized, placebo-controlled, parallel-group, double-blind Phase<br \/>\n      III clinical trial to evaluate the efficacy and safety of MK-8931 in<br \/>\n      subjects with prodromal Alzheimer\u2019s disease. The study is designed to<br \/>\n      enroll 1500 participants. Patients will be randomized to receive<br \/>\n      placebo, or 12 mg or 40 mg MK-8931, once daily. The primary efficacy<br \/>\n      outcome of the study is change from baseline in the Clinical Dementia<br \/>\n      Rating Scale-Sum of Boxes (CDR-SB) score following 104 weeks of<br \/>\n      treatment.\n    <\/p>\n<p>\n      <b>About BACE Inhibition and MK-8931<\/b>\n    <\/p>\n<p>\n      The amyloid hypothesis asserts that the formation of amyloid peptides<br \/>\n      that lead to amyloid plaque deposits in the brain is a primary<br \/>\n      contributor to the underlying cause of Alzheimer&#8217;s disease. BACE is<br \/>\n      believed to be a key enzyme in the production of amyloid \u03b2 peptide.<br \/>\n      Evidence suggests that inhibiting BACE decreases the production of<br \/>\n      amyloid \u03b2 peptide and may therefore reduce amyloid plaque formation and<br \/>\n      modify Alzheimer\u2019s disease progression.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Patients Suffering from Alzheimer\u2019s Disease<\/b>\n    <\/p>\n<p>\n      Merck is committed to advancing the understanding and treatment of<br \/>\n      Alzheimer&#8217;s disease. We are currently evaluating several innovative<br \/>\n      mechanisms in Alzheimer&#8217;s disease, including candidates designed to<br \/>\n      modify disease progression and improve symptom control. Merck&#8217;s major<br \/>\n      effort in disease modification is our lead investigational BACE<br \/>\n      inhibitor, MK-8931, that is being evaluated in late stage clinical<br \/>\n      trials for mild to moderate and prodromal Alzheimer\u2019s disease. In<br \/>\n      addition, Merck is conducting a Phase II clinical trial for MK-7622, an<br \/>\n      investigational adjunctive therapy to donepezil for the symptomatic<br \/>\n      treatment of participants with mild to moderate disease.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=5674aea16da2101f39c657e32a30aff9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=b22eb375c52f506d4c2be88d11c4d7d7\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=194feaadf9113f51909d40618b685fd5\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=d24e4a6af809ab092153d99f17a77059\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50765556&amp;newsitemid=20131210005300&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=b7395494322b176a6e4ab65b188edfce\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lappetito, 267-305-7639<br \/>Justine        O\u2019Malley, 908-423-2021<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data Monitoring Committee recommends continuation of Phase II\/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. The Data Monitoring Committee (DMC) for the Phase II\/III \u201cEPOCH\u201d study in patients with mild to moderate Alzheimer&#8217;s disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol. The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months. Based upon the DMC\u2019s recommendations, Merck will continue enrollment of the EPOCH study. In addition, Merck will initiate<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-742277","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data Monitoring Committee recommends continuation of Phase II\/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. The Data Monitoring Committee (DMC) for the Phase II\/III \u201cEPOCH\u201d study in patients with mild to moderate Alzheimer&#039;s disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol. The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months. Based upon the DMC\u2019s recommendations, Merck will continue enrollment of the EPOCH study. In addition, Merck will initiate\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/\",\"name\":\"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2013-12-10T07:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/","og_locale":"en_US","og_type":"article","og_title":"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com","og_description":"Data Monitoring Committee recommends continuation of Phase II\/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral \u03b2-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. The Data Monitoring Committee (DMC) for the Phase II\/III \u201cEPOCH\u201d study in patients with mild to moderate Alzheimer's disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol. The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months. Based upon the DMC\u2019s recommendations, Merck will continue enrollment of the EPOCH study. In addition, Merck will initiate","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:31+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/","name":"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2013-12-10T07:00:00+00:00","dateModified":"2023-03-22T04:04:31+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20131210005300r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-advances-development-program-for-investigational-alzheimers-disease-therapy-mk-8931\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Advances Development Program for Investigational Alzheimer\u2019s Disease Therapy, MK-8931"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7a84e600-36ec-4596-b92c-536b554acd1a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Advances-Development-Program-for-Investigational-Alzheimers-Disease-Therapy-MK-8931-2013.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742277\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742277"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}